Sandoz board chair ‘convinced that common sense will ultimately prevail’ on US pharma tariffs

In an exclusive interview with Swissinfo, Gilbert Ghostine, the chair of the board of pharma firm Sandoz, says he remains optimistic despite looming tariff hikes. Pharmaceuticals have so far been excluded from the sweeping new tariffs announced by the United States, but the sector may not be spared for long. The pharma industry, including generics, could be hit with 25% tariffs or more. A company like Sandoz, which specialises in generic and biosimilar drugs, depends on tight supply chains and thin margins, so the prospect of tariffs means reviewing its US strategy and potential price hikes. Swissinfo met Sandoz board chair Gilbert Ghostine at the company’s headquarters in Basel. In an exclusive interview, he analyses the impact that US tariffs would have on the company, the pharma sector's dependence on certain regions for sourcing, and ways to avoid future drug shortages. Gilbert Ghostine: key facts - Born in 1960 - Lebanese and Canadian citizenship - “Serial globe trotter”: has ...